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RÉSUMÉ
Les espèces réactives oxygénées (ROS) sont produites de façon naturelle dans les
cellules. Cependant, une production excessive ou une insuffisance dans le processus de
leur élimination est associée à différentes maladies. Ainsi, les dernières années ont vu les
ROS émerger comme des joueurs importants dans la pathogenèse des maladies
cardiovasculaires, comme l’hypertension, l’athérosclérose et l’hypertrophie cardiaque,
ainsi que les complications vasculaires du diabète. Il est connu que les ROS peuvent
oxyder certains constituants cellulaires et qu’elles activent les voies de signalisation
impliquées dans la croissance cellulaire, l’hypertrophie, la prolifération et la migration,
ainsi que la survie, qui sont des événements caractéristiques du remodelage
cardiovasculaire. Les voies de signalisation les plus importantes sont celles des MAPK et
de la phosphatidylinositol-3-kinase (PT3-K)/protéine kinase B (PKB). Cependant, les
mécanismes moléculaires par lesquels les ROS déclenchent l’activation de ces voies
restent à être clarifiés. Bien qu’un rôle des récepteurs et non récepteurs protéines
tyrosines kinases (« PTKs ») dans la médiation de la phosphorylation des ERKI/2 par le
H202 soit suggéré, une implication possible des tyrosines kinases dans l’activation de
PKB et de Pyk2 par le stress oxydatif n’a pas encore été clarifié dans les cellules du
muscle lisse vasculaire (« VSMC »). Donc, l’objectif principal de notre étude était
d’examiner le rôle des récepteurs et non récepteurs PTK dans l’activation de la PKB par
le H202 dans la lignée cellulaire de «VSMC » AlO. Ces cellules sont isolées de l’aorte
thoracique de l’embryon de rat.
La phosphorylation de la PKB induite par le H202 a été complètement inhibée par
le prétraitement des cellules avec l’AG1024, un inhibiteur pharmacologique spécifique
du IGF-1R-PTK (« insulin-like growth factor typel receptor PTK»), alors que J’AG1478,
un inhibiteur spécifique du EGFR-PTK (« epidermal growth factor receptor PTK ») n’a
pas eu d’effet inhibiteur sur la phosphorylation de la PKB. De même, la phosphorylation
de Pyk2, Src et ERK1/2 induites par le H202 ont été complètement inhibées par AG1024
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et non par AG1478. L’implication du «IGF-1R> dans la signalisation induite par F1202 a
aussi été démontrée par le fait que le H202 augmente la phosphorylation en tyrosine des
sous unités f3 du «IGF-1R » et que le prétraitement au AG1024 a inhibé cette
phosphorylation. De plus, l’inhibition pharmacologique de Src a diminué de façon
significative la phosphorylation de la PKB et de Pyk2 par le H202. Tout comme l’effet de
l’AG1478, l’AG1295, un inhibiteur spécifique du PDGFR-PTK («platelet-derived growth
factor receptor PTKx’) n’a pas inhibé la phosphorylation de PKB ni de ERK1/2 induite
par le H202, alors qu’il a supprimé complètement la réponse au «PDGF». En conclusion,
nos résultats suggèrent que le «IGF-1R>, et non pas le «EGFR» ni le «PDGFR» joue un
rôle critique dans la médiation des évènements induits par le H202 et qui sont
responsables de l’hypertrophie et de la croissance des «VSMC ».
Mots clés: ROS, H202, MAPK, PKB, Src, Pyk2, récepteurs et non récepteurs PTK, IGF
1R, VSMC.
VABSTRACT
Reactive oxygen species (ROS) are produced normally in the ceils, but their
excessive production or a Jack in their elimination process is associated with various
dïseases. Thus, ROS have emerged in the recent years as important players in the
pathogenesis of cardiovascular disorders, such as hypertension, atherosclerosis and
cardiac hypertrophy as well as in the vascular complications of diabetes. ROS are known
to modify the celi components by oxidation and to activate signaling pathways
responsible of celJ growth, hypertrophy, proliferation, and migration as well as survival,
which are characteristic events in cardiovascular remodeling. The most important of these
pathways are the mitogen-activated protein kinases (MAPKs) and the
phosphatidylinositol-3 -kinase (P13-K)/protein kinase B (PKB) pathway. However, the
precise molecular mechanisms by which ROS trigger the activation of these pathways
remain to be clarified. AJthough a role for receptor and non-receptor protein tyrosine
kinases (PTKs) in mediating H202-induced ERK1/2 phosphorylation has been suggested,
a possible involvement of tyrosÏne kinases in PKB and Pyk2 activation by oxidative
stress has not yet been clanfied in VSMC. Therefore, the main objective of our studies
was to investigate the role of receptor and non-receptor tyrosine kinases in H202-induced
PKB activation in AlO VSMC. These ceils are obtained from rat embryonic thoracic
aorta.
H202-induced PKB phosphorylation was completely abolished by pretreatment of
the ceils with AG1024, a specific phannacological inhibitor of the insulin-like growth
factor type 1 receptor PTK (IGF-1R-PTK), whereas AG1478, the specific inhibitor of the
epidermal growth factor receptor PTK (EGFR-PTK) did flot have any inhibitory effect on
PKB phosphorylation under the same conditions. Similarly, H202-induced
phosphorylation of Pyk2, Src and ERK1/2 phosphorylation were completely blocked by
AG1024 but not by AG1478. The involvement of the IGF-IR in H202-induced signaling
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was also demonstrated by the resuits showing that H202 enhanced the tyrosine
phosphorylation of the r3-subunit of IGF-IR and that AG1024 pretreatment markedly
inhibited this phosphorylation. Moreover, pharmacological inhibition of Src significantly
decreased H202-induced PKB and Pyk2 phosphorylation. Similar to the effect of
AG1478, AG1295, the specific inhibitor of the platelet-denved growth factor receptor
PTK (PDGFR-PTK) failed to inhibit H202-induced PKB and ERKI/2 phosphorylation,
whïle it abrogated the PDGF-induced response under the same conditions. Taken
together, our data suggests that IOF-1R, but flot EGFR nor PDGFR plays a critical role in
mediating H202-induced signaling events which are important mediators for hypertrophy
and growth in VSMC.
Key words: ROS, H70,, MAPK, PKB, Src, Pyk2, receptor and non-receptor PTK, IGF
1R, VSMC.
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CHAPTER 1
INTRODUCTION
2Evidence generated during the recent years has suggested a crucial role for
reactive oxygen species (ROS) in the pathophysiology of cardiovascular disorders
including hypertension, atherosclerosis and restenosis after angioplasty [1-3] as well as in
diabetes (reviewed in [4]) and cancer (reviewed in [5]). Therefore, there is a lot of
interest to understand the mechanism of ROS generation, its elimination and
identification of its cellular targets. Thus, the objective of this section is to provide a brief
overview on these aspects of ROS and its relationship in the pathophysiology of
cardiovascular disease.
1.1 Tlie multiple sources of ROS
ROS are formed as intermediates in redox reactions, leading from molecular
oxygen (02) to water (H20) [6]. They are small, quickly diffusibie and highly reactive
molecules [7] and are classified into superoxide anion (02), hydroxyl radical (OH),
hydrogen peroxide (H202) and peroxynitrite (0N00) [8]. Their major intracellular
source is the mitochondna which converts 1-2% of consumed 02 into 02 [7]. 02 andlor
H202 can also be derived from NAD(P)H oxidase, xanthine oxidase, cyclooxygenase,
lipoxygenase, heme oxygenases, peroxidases, as well as hemoproteins such as heme and
hematin (reviewed in [9]). The univalent reduction of 02 leads to 02, which is relatively
unstable and short-lived because of its unpaired electron [10] (fig. 1.1).
3011
e- Metals
02 02 11202
NAD(P)H SOD Catalase
oxidase
figure 1.1: Simplified scheme showing key steps in the production of reactive
oxygen species (ROS). The most important ways of ROS generation are shown here.
One electron from NAD(P)H is transfened to molecular Oxygen (02) by NAD(P)H
oxidase to generate superoxide anion ÇOj), which can be converted to hydrogen peroxide
(H202) either spontaneously or by superoxide dismutase (SOD). In presence of metals,
H202 can be converted to Hydroxyl anion ÇOH). (Adapted from Ref. [li]).
41.2 The NAD(P)ll oxidase
The major source of ROS in the vascular walI is the NAD(P)H oxidase [12j,
which is a complex enzyme system cornposed of many subunits including p22phox,
p47phox, the GTPase Rac and the recently identified Noxi and Nox4 [12-15]. The
NAD(P)H oxidase catalyzes 02 production by the one electron reduction of 02 where
NAD(P)H is the electron donor:
202 + NAD(P)H —* 202 + NAD(P) + W [16].
NAD(P)H oxidase is activated in hypertensive animais [17;18] as weli as in
human hypertensive subjects [19;20] and it is believed to act as a major player in the
deveiopment of atherosclerosis [21]. Particuiarly, p22phox was shown to play an
important role in agonist-induced ROS generation and gene expression in VSMC in
response to Angiotensinil (Angil), Tumor necrosis factor Œ (TNF-a) and thrombin
[12;22-24]. Moreover, Noxi seems to be upregulated by proliferative stimuli, such as
Angiotensinli (Angil) and plateiet-derived growth factor (PDGf) in VSMC [25].
1.3 The ROS scavenging systems
Under physiological conditions, 02 undergoes dismutation either spontaneously
or by a reaction catalyzed by superoxide dismutase (SOD) to produce H202. Dismutation
of 02 by SOD ïs favored at low concentrations of 02 and at high concentrations of
SOD, which happens under physiologicai conditions. H202 is much more stable than 02,
can cross celi membranes and lias a longer haif-life. Normaiiy it is scavenged by catalase
and giutathione peroxidase to produce H20 [101. In the presence of metal-containing
moiecules such as Fe2, H202 can also be reduced to generate the extremeÏy active
5hydroxyl radical ÇOH) that causes damage to the ceil components [6]. In the glutathione
peroxidase reaction, glutathione (GSH) is oxidized to glutathione disulfide (GSSG),
which can be converted back to GSH by glutathione reductase in a NADPH-consuming
process (fig. 1.2). Several forms of SOD are known: copper-zinc SOD (Cu/Zn SOD),
mitochondrial or manganese SOD (Mn SOD) and iron-containing SOD (Fe SOD)
[26;27].
Normally, the rate of ROS production is balanced by the rate of their elimination.
However, in pathological conditions, a disequilibrium between ROS generation and
elimination resuits in increased ROS bioavailability leading to oxidative stress [2$].
Furthermore, in case of excessive production, 02 reacts with nitric oxide (NO) to
produce the very hamiful ONOO [29].
6NADH o. NAD(P)H
Electron transport chain
NAD(P)H oxidase
Xanthine oxidase, etc....
NADNADP+ NO
0N00
H70
GSSG
NAD(P)H
Figure 1.2: Production and elimination of 02 and H202. 02 can undergo dismutation
by superoxide dismutase (SOD) to produce H202. H202 is scavenged by catalase or
Glutathione peroxidase to produce water (H20) whule in the sarne reaction, Glutathione
(GSH) is converted to Glutathione disulfide (GSSG), which can be converted back to
GSH by Glutathione peroxidase. In presence of metals, H20, can be converted to
Hydroxyl anion (‘oH). It is noteworthy that high levels of ‘02 may lead to the generation
of peroxynitrite anion (0N00) since 02 can react with nitric oxide (NO).
OH
NADP+
71.4 Re%ulation of ROS production by vasoactive peptides and growth factors
An increasing number of studies have demonstrated that vasoactive peptides
mediate their responses through the generation of ROS. The potent vasoconstrictor
endothelin-1 (ET-I) bas been shown to activate NAD(P)H oxidase resulting in ROS
generation in endothelial cells [30] and to increase H202 levels via its subtype A receptor
(ETA receptor) in pulmonary smooth muscle cells [31]. Similarly, a role for ROS
generation in mediating ET-1-induced activation of various signaling pathways, such as
ERK1/2, PKB and Pyk2 [32] as well as JNK and p3$mapk [33] has also been
demonstrated. Moreover, ET-1, through ETA receptor, bas also been implicated in the
increased vascular levels of 02 in both low-renin hypertension and chronic ET-1-infused
rats models of hypertension [34;35].
Another important vasoactive peptide, Angli is also known to induce ROS
generation in many ccli types including cardiomyocytes [36], endothelial cells [37] and
VSMC [12]. In hypertension, Angil activates the NAD(P)H oxidase thereby enhancing
the ROS generation [12;38]. Furthermore, H202 appears to play a direct role in AngII
induced vascuÏature hypertrophy [39;40] (Fig. 1.3).
Growth factors such as the epidermal growth factor (EGF) [41], the PDGF [42]
and cytokines were also shown to induce the generation of ROS such as 02 and H202 in
nonphagocytic celis [43]. Transforming growth factor-betal (TGF-betal), which is
abundantly expressed in pulmonary hypertension, induced expression of Nox4 and
likewise increased production of ROS, in freshly isolated human pulmonary artery
smooth muscle celis [44]; this is believed to be an important mechanism in pulmonary
vascular remodeling.
8SrcIPyk2
&Ior RTKs
I
PI3K
I
1
mTOR
—, p7Os6k
Figure 1.3: Regulation of ROS generation by vasoactive peptides. The vasoactive
peptides Angil and ET-1 are known to increase the ROS generation in many ccli types,
particuiarly in VSMC, by activatÏng the NAD(P)H oxidase through an as yet unknown
mechanism. Endogenously produced ROS activate many protein tyrosine kinases, such as
c-Src, Pyk2 and receptor tyrosine kinases (RTKs) that act as upstream regulators of
MAPK as weii as P13-KIPKB pathway.
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91.5 ROS in vascular diseases
There is increasing evidence that oxidative stress is involved in the initiation and
progression of cardiovascular disease. An enhanced ROS generation is observed at sites
of vascular injury and has been related to the development of restenosis/ atherosclerosis
[45]. A key role for vascular NAD(P)H oxidases in the development of human
atherosclerosis was reported recently [46-4$]. Originally, it was thought that ROS are
involved in low density lipoproteins (LDL) oxidation, a key step in the initiation and
progression of atherosclerosis [49]. More recently, studies have shown that ROS are also
implicated in endothelial dysfunction, increased contractility, VSMC migration, growth
and apoptosis, inflammation and increased depositions of extracellular matnx proteins,
whïch are important factors in hypertensive damage [50].
The decrease in NO bioavailability bas been correlated to an ïncrease in in
hypertension and hypercholesterolemia (reviewed in [51]). O2 reacts with NO and forms
0N00, leading to a decreased NO bioavailability. Elevation in O2 levels contributes to
impaired endothelial function associated with atherosclerotic disease [52].
1.5.1 ROS in genetic and experimental hypertension
A considerable number of studies have shown that hypertension is associated with
an elevated level of ROS and also with an impairment of endogenous antioxidant defense
mechanisms (reviewed in [53]). ROS, such as H2O2 and O2 are increased in vessels,
heart and lddneys of the spontaneously hypertensive rats (SHR) [16;54], the obesity
prone and the Dahi salt-induced sensitive rats [55;56]. In SHR, the increased NAD(P)H
induced 0j generation appears to be associated with NAD(P)H oxidase subunit Nox4
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overexpression and enhanced oxidase activity [17;57]. Polymorphisms in the promoter
region of the p22phox gene have also been identified in SHR [58]. Renal NAD(P)H
oxidase upregulation has been reported in young SHR [17J. Vascular O2 and oxidant
markers are also increased in aortas of mice with deoxycorticosterone acetate-sait
(DOCA-salt)-induced hypertension [18] as well as in hypertensive models created by
infusion of ET-1 [34;59;60]. In a study performed on Noxi-deficient mice, Matsuno et al.
demonstrated that Noxi- derived ROS are involved in AngII-induced hypertension and
this occurred by reducing the bioavailability of NO [61]. Recently, Callera et al.
demonstrated that ET-1-induced oxidative stress in DOCA-sait hypertension not only
involves NAD(P)H oxidase, but also mitochondria-derived ROS [62].
Experimentally, generators of O2 were shown to abolish endothelium-dependent
relaxation of aortic rings isolated from SHR [63], induce contraction of mesentenc beds
[64] and to increase chlonde reabsorption by isolated thick ascending limbs of the loop of
Henle [65]. Makino et al. demonstrated that infusion of H202 in the renal medulla of
whole rats increased blood pressure and decreased urine flow as well as sodium excretion
[66]. In accord with this study, Kopkan et al. demonstrated that enhanced O2 generation
in AngII-induced hypertensive rats modulates renal hemodynamic and tubular
reabsorptive function which leads possibly to sodium retention [671. It was also shown
that H202 as well as Oj regulated vascular contraction by increasing intracellular
calcium concentration ([Ca2]) in pig coronary artery SMC [6$;69] and in rat mesenteric
arteries with greater effects in SHR versus normotensive Wistar Kyoto (WKY) rats
[69;70].
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1.5.2 ROS in human hypertension
Recent clinical studies have demonstrated increased oxidative stress and reduced
antioxidant status in patients with essential hypertension, renovascular hypertension and
malignant hypertension. In these studïes, the leveis of plasma thiobarbituric acid-reactive
substances and $-epi-isoprostames, biomarkers of iipïd peroxidation and oxidative stress,
were shown to be increased [19;20;71;72]. In mild-to-moderate hypertension, iipid
peroxidation and oxidative stress are not increased [73], suggesting that ROS may flot be
cntical in the early stages of human hypertension, but could be more important in severe
hypertension. Activation of the renin-angiotensin system has been proposed as a mediator
of NAD(P)H oxidase activation and ROS production [16;74-76]. In fact, some of the
therapeutic blood pressure-Iowering effects of AT1 receptor blockers and angiotensin
converting enzyme (ACE) inhibitors have been attnbuted to NAD(P)H oxidase inhibition
and decreased ROS production [77;7$J. An association between a p22phox gene
polymorphism and NAD(P)H oxidase-mediated 02 production in the vascular wall of
patients with hypertension and atherosclerosis bas aiso been descnbed [79].
1.5.3 ROS in heart failure
Experimental and clinical studies have suggested an increased production of ROS
in animais and in patients with acute and chronic heart failure (reviewed in [$0]). ROS
are released during ischemia and ischemic reperfusion (reviewed in [$1]). Moreover,
oxidants production is increased by Angil and catechoiamine, two endocrine factors
known to ïnduce cardiac remodeling [$2;83]. The possible sources are many and include
xanthine and NAD(P)H oxidoreductases, cyclooxygenases, mitochondn ai electron
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transport chain and activated neutrophïls. Excessive NO denved from NO Synthase
seems to be implicated in the pathogenesis of chronic heart failure: NO reacts with O2 to
form ONOO, a reactïve oxidant which impairs cardiac function. Increased oxidative and
nitrosative stress activates also the nuclear enzyme poly-ADP-nbose polymerase which is
known to contribute to pathogenesis of cardiac and endothelial dysfunction associated
with myocardial infarction, congestive heart failure, hypertension, atherosclerosis and
diabetes (reviewed in [$0]).
1.5.4 ROS in vascular complications of diabetes
Oxidative stress can induce abnormal changes in intracellular signaling and result
in chronic inflammation and insulin resistance. It is known that hyperglycemia as well as
free fatty acids stimulate ROS production [84]. In diabetes, plasma levels of ROS are
significantly elevated [85]. Inflammation and oxidative stress have been linked to insulin
resistance in vivo, not only in type 2 diabetes, but also in obese, nondiabetic individuals
and in patients with metabolic syndrome (reviewed in [4]). Moreover, NAD(P)H oxidase
components are upregulated in vascular tissues of animal models and patients suffering
from diabetes and obesity (reviewed in [86]). High levels of ROS trigger the activation of
senne/threonine kinase cascades such as c-Jun N-terminal kinase, nuclear factor-kappaB
(NE-KB), and others that in tum phosphorylate multiple targets, including the insulin
receptor and the insulin receptor substrate (IRS) proteins. Increased serine
phosphorylation of IRS reduces its ability to undergo tyrosine phosphorylation and may
accelerate the degradation of IRS-1 leading to an aberrant insulin signaling and insulin
resistance (reviewed in [4]).
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Studies performed in vitro could also explain in part the molecular mechanism by
which ROS can contribute to insulin resistance. H202 as well as a ROS inducer, diamide
was found to inhibit insulin signaling in cultured rat VSMC by blocking the insulin
induced protein kinase B (PKB) phosphorylation on Senne 473 (Ser473) [87]. In addition,
H202 pretreatment also attenuated the insulin receptor bïnding and insulin receptor
autophosphorylation in this study [87]. The negative regulation of PKB could contribute
to insulin resistance because its activation by insulin is critical in stimulating glucose
transport, glycogen synthase, protein synthesis, antilipolysis and suppression of hepatic
gluconeogenesis [88]. Moreover, studies have suggested that insulin might protect VSMC
from remodeling by inhibiting apoptosis [$9] and migration [90]. Taken together, it is
possible that ROS, through their effects on the insulin signaling pathway, may contribute
to cardiovascular disease.
1.6 The ïntracellular effects of ROS
Ceils respond to oxidant injury with the activation of multiple signal transduction
pathways that serve to coordinate the cellular response and determine the outcome. High
levels of ROS resuit in severe damage to the celi components (lipids, proteins,
carbohydrates and DNA). ROS-induced oxidative modification of proteins and lipids can
modify the structure and function of proteins and lipid bilayers resulting in cellular
dysfunction. In the vasculature, 02 and H202 are particularly important since they act as
inter- and intracellular signaling molecules. OH induces local damage, whereas 02 and
H202 can travel some distance from their site of generation (reviewed in [9]). The
biochemical events by which ROS mediate cellular dysfunction and contnbute to
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pathogenesis of vascular diseases include changes in gene expression and celi signaling
pathways. Two major signaling pathways, the mitogen-activated protein kinase (MAPK)
and the phosphatidylinositol-3-kinase (P13-K)/protein kinase B (PKB) pathways, have
been identified as important targets of ROS (Fig. 1.3). Aberrant activation of these
pathways in the pathogenesis of vascular diseases has been suggested (Fig. 1.6).
1.7 The MAPK pathway
MAPK are a family of ubiquitous serine/threonine protein kinases, classicaÏly
associated with celi growth, differentiation and death [91]. MAPK are activated in
response to a variety of extemal stimuli such as growth factors, hormones and stress, as
well as vasoactive peptides and ROS (reviewed in [92;93]). 0f the major mammalian
MAP kinases, extracellular signal-regulated kinases (ERK1/2), p38MAP kinase
(p38mapk), c-Jun N-terminal kinases (JNK) and ERK5 are the best characterized.
MAPK are activated by MAPK kinase (MAPKK also known as MEK) which, in tum are
activated by MAPKK kinase (MAPKKK also known as MEKK or RaO. The
MAPKKKIRaf are serine/threonine kinases and are activated by phosphorylation andlor
by their interaction with small GTP-binding protein of Ras/Rho family through adaptor
proteins Son of sevenless/Growth factor receptor binding protein 2 ((Sos)IGrb2)).
Activated MAPKKKIRaf phosphorylate and activate MAPKKJMEK, which then
phosphorylate MAPK on Thr and Tyr residues located in the activation ioop of the
kinases (Fig. 1.4). Activated MAPKs phosphorylate target substrates on Ser or Thr
residues followed by a proline, such as p9Orsk, and transcription factors such as c-Jun,
CHOP, CREB and MEF-2 (reviewed in [94]). ERK1/2, phosphorylated by MEK1/2
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(MAP/ERK kinase), is a major growth signaÏing kinase, whereas p38mapk and JNK,
phosphorylated by IVIEK3/6 and MEK4/7 respectively, influence celi survival, apoptosis,
differentiation and inflammation [91]. ERK5, regulated by MEK5, is invoÏved in protein
synthesis, celi cycle progression and ceil proliferation [95-97].
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Figure 1.4: Schematic model showing the signaling cascade induced by receptor
tyrosine kinases leading to ERK1/2 activation. kisulin-like growth factor (IGF-1), by
binding to its receptor (IGF-1R) enhances tyrosine phosphorylation of the insulin
receptor substrates (TRSs). Phosphorylated IRSs recruit Src homology 2 (SH2) domain
containing proteins, such as Grb2ISos. Ibis complex formation triggers the activation of
RasIRafJMEKIERK1/2 signaling pathway, which is important for celi growth,
proliferation and differentiation. Similarly, epidermal growth factor (EGF) and platelet
derived growth factor (PDGF) activate ERK1/2 signaling cascade. However, in this case,
Grb2/Sos interacts directly with tyrosine phosphorylated EGFR or PDGFR, triggering
thereby the activation of ERKÏ/2 pathway.
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1.7.1 Activation of MAPK pathway by ROS
In the Iast few years, many reports have shown that ROS activate the MAPK
pathway in different celi types, including Rat-2 fibroblasts [98], rabbit renal proximal
tubular celis [99], Chinese hamster ovary (CHO) cells [1001, rat cardiomyocytes and
heart fibroblasts [101] as well as VSMC [11;102;103]. Moreover, ROS generation was
shown to be cntical in the activation of MAPK by Angli [104;105] and ET-1 [32;105] in
VSMC. Despite an overwhelming evidence supporting an involvement of ROS in
vasoactive peptide-induced ERK1/2 sïgnaling, ROS-independent mechanism of this
response has also been documented in some ccli types [106].
1.7.2 MAPK activation in cardiovascular diseases
Several unes of evidence have indicated that an aberrant activation of the MAPK
is often associated with vascular remodeling in cardiovascular diseases. For example, the
enhanced activation of vascular MAPK has been demonstrated in different models of
hypertension [107;108]. Activation of MAPK by Angli and ET-1 in VSMC was shown to
be invoived in vascular changes associated with hypertension [109;110J and a role of
MAPK in VSMC contraction and migration has also been suggested [111;112]. Thus, a
heightened activation of MAPK may be responsible for aberrant vascular remodeiing and
muscle contractility, which is a haiimark of vascular disease.
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1.8 The phosphatidylinositol-3-kinase (P13-K)/protein kinase B (PKB) pathway
Another key cellular signaling pathway that plays an important role in ceil
growth, survival, proliferation and gene expression is P13-KJPKB pathway. P13-K is a
heterodimeric lipid kinase, which is divided into three classes that are different in
structure and mechanism of regulation [1131.
1.8.1 Classification of P13-Ks
Class I P13-K are activated by receptor tyrosine kinases and G protein-coupled
receptors (GPCRs).They catalyze the phosphorylation of phosphatidylinositol (PI), PI 4-
phosphate and PI 4,5-biphosphate in the 3’ position of the inositol ring. This reaction
promotes the generation of PI 3’-P, PI 3, 4-biphosphate (PI-3,4-P2) and PI-3, 4, 5-
triphosphate (PIP3) [114]. Class II P13-K possesses a lipid binding domain and generates
PI 3’-P as well as PI-3,4-P2 whereas class III P13-K generates only PI 3’-P [114]. Class I
P13-Ks represent the dominant form in cardiovascular tissues [115] and are divided into
class lA and lB. The llOkDa catalytic subunit of class TA exists in three isoforms:
pi lOa, p11013 and pi 106. Similarly, the 85kDa regulatory subunit of class TA exists in
three isoforms: p$5Œ, p8513 and p55y, which are products of three different genes [116].
Class TA of PI3-Ks are typically activated in response to tyrosine kinase-coupled stimuli
[115]. The p85 subunit contains the Src homology-2 (SH-2) domain and is able to
interact with phosphorylated tyrosine residues on receptor or other docking proteins,
leading to the stimulation of the 110 kDa catalytic subunit, then pi 10 catalyzes the
phosphorylation of PI substrates into PI 3’-P, PI-3’,4-P2 and PI-3,4,5-P3 (PW3). PW3
binds to Pleckstrin homology (PH) domain of several proteins which are downstream
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targets of P13-K, such as PKB. In contrast, class lB consist of a catalytic subunit (pi lOy)
and a regulatory subunit (p101) and are usually activated by GPCR activation [115].
PKB, also known as Akt, which mediates several effects of P13-K, exists as three
isoforms: PKBa/Akti, PKBf3/Akt2 and PKBy/Akt3; each isoform possesses an amino
terminal PH domain, a kinase domain and a carboxy-terminal regulatory domain. PKB is
rapidly activated in response to insulin [117;118J, AngIl [119], ET-i [32] and many other
growth factors [120-123] in a phosphatidylinositol-3-kinase (P13 -K)-dependent manner.
Binding of PW3 to PKB recmits it to the plasma membrane for phosphorylation
by phosphoinositide-dependent kinases 1 (PDK-1) and 2 (PDK-2). PDK-1
phosphorylates PKB at Threonine 30$ (Thr308) in the catalytic domain whule putative
PDK-2 phosphorylates it at Senne 473 (Ser473) in the C-terminal regulatory domain of
PKB (reviewed in [124]). Activated PKB phosphorylates several downstream substrates,
such as glycogen synthase kinase-313 (GSK-3f3), Forkhead transcription factor (FKHR),
Bcl-2-associated death (BAD), Caspase 9, mammalian target of rapamycin (mTOR),
Mdm2, nuclear factor-icB (NF-KB) and endothelial nitric oxide synthase (eNOS)
(reviewed in [124;125]). Phosphorylated form of these substrates regulates diverse
cellular functions, such as glucose transport, cell growth, gene expression, celI survival
and death as well as protein synthesis [119](reviewed in [126]) (Fig. 1.5).
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1.8.1 Activation of PKB by ROS
Exogenously added H202 was shown to enhance the phosphorylation of PKB on
Ser473 in many celi types including NIH3T3, MCF-7 and malignant HeLa ceils [127],
Rat-2 fibroblasts [98], CHO celis [100], renal celis [99], cardiomyocytes and heart
fibroblasts [101] as well as VSMC [11;102]. Moreover, an intermediary role of ROS in
mediating PKB activation by AnglI [128] and ET-1 [32] in VSMC has also been
demonstrated.
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Figure 1.5: Schematic modet showing the signaling cascade induced by receptor
tyrosine kinases leading to PKB activation. Insulin-like growth factor (IGF-l), by
binding to its receptor (IGF-1R) enhances tyrosine phosphorylation of the insulin
receptor substrates (IRSs). Phosphorylated IRSs recruit Src homo[ogy 2 (SH2) domain
containing proteins, such as Grb2/Sos and p85 subunit of the lipid kinase P13-K, leading
to activation of P13-K. Activated P13-K catalyzes the phosphorylation of PW2 into PW3.
PW3 binds to Pleckstrin homology (PH) domain of PKB and recruits it to the plasma
membrane for phosphorylation by PDKÏ/2. Actïvated PKB phosphorylates several
targets sucli as mTOR, GSK-3f3, FKHR, BA and Caspase that regulate metabolism, gene
expression and ceil survival. Similarly, epidermal growth factor (EGF) and platelet
derived growth factor (PDGF) activate P13-KIPKB signaling cascade. However, in this
case, p85 subunit interacts directly with EGFR or PDGFR, triggering thereby the
activation of the pathway.
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The precise upstream mechanisms by which ROS activate MAPK and P13-KJPKB
pathways remain unclear. However, a potential role for both growth factor receptors
[99; 101; 103; 127; 129], and non-receptor protein tyrosine kinases [98-100; 103] as signal
transducers of H202-induced responses bas been suggested.
1.9 The epidermal %rowth factor receptor (EGfR)
The EGFR is a receptor tyrosine kinase that is ubiquitously expressed in a variety
of celi types, with the most abundant expression in epithelial ceils and many cancer celis
[130-132]. It contains an extracellular ligand binding domain, a single transmembrane
domain and a cytoplasmic tyrosine kinase autophosphorylation and regulatory domain
(reviewed in [133]). EGFR belongs to a family containing three other members (ErbB2,
ErbB3 and ErbB4) that undergo homodimenzation or heterodimerization to induce
autophosphorylation and receptor tyrosine kinase activation in response to ligand binding
[131;134J. Dimerization activates the intrinsic tyrosine kinase activity of the intracellular
domain at different residues, resulting in the recruitment of the SH-containing domain
proteins, which trigger downstream events. The phosphorylation of EGFR on tyrosine
1068 (Tyr1068) is followed by recruitment of the adaptor protein Grb2, leading to the
activation of RasJERK1/2 pathway (Fig. 1.4).
1.9.1 Transactivation of the EGFR
The EGFR can also undergo phosphorylation in a ligand-independent manner by
a process called transactivation and tngger the response of many agonists, such as Angli,
ET-1, thrombin, lysophosphatidic acid, H202 and others. Thus, EGFR was identified as
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an essential link in AngII-mediated activation of MAPK [135;136] and PKB [137;138J in
VSMC. In the same context, Voisin et al. have reported that the activation of EGFR by
Angil is necessary for increasing protein synthesis in vitro in cultured aortic smooth
muscle celis and in vivo in the rat aorta as well as in small resistance arteries [139].
Similarly, ERK1/2 activation by ET-1 appears to be dependent on transactivation of
EGFR in Rat-1 fibroblasts [140], VSMC [141], cardiomyocytes [142] and rat mesangial
cells [143].
H202 has been shown to enhance tyrosine phosphorylation of EGFR in
endothelial ceils [144], renal cells [99], HeLa cells [127] as well as in VSMC
[129;145;146]. Whether H202 directly activates the intnnsic tyrosine kinase activity of
EGFR or modulates signaling molecules that transactivate the receptor is stiil unclear.
There are some reports proposing that ROS may exert their effects through targeting the
cysteine regions of the active sites of tyrosine phosphatases, which in tum activates
tyrosine kinases [147]. In fact, H202 was shown to inhibit the dephosphorylation of the
EGFR by inhibiting a tyrosine phosphatase [148]. Some other reports suggest that ROS
may activate receptor tyrosine kinases by generating growth factors, such as heparin
binding EGF-like growth factor (HB-EGF) through metalloprotease-dependent cleavage
[129]. ROS production [149] and metalloprotease-dependent RB-EGF generation are also
implicated in EGFR transactivation by different GPCR agonists in many ceil types
[150;151]. Frank et al. have demonstrated that both mechanisms are necessary for EGFR
transactivation by AnglI in VSMC [152;153].
The tyrosine phosphorylation of the EGFR by ROS is accompanied by its
association with Grb2 leading to activation of ERK1/2, which appears to be an important
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mechanism in triggering MAPK activation induced by H202 in vanous celi types
[99;1O1;103;145;154J. On the other hand, studies on the involvement of EGFR
transactivation in H202-induced PKB phosphorylation gave discrepant resuits: for
example, EGFR transactivation was implicated in H202-induced PKB phosphorylation in
HeLa cells [127], but flot in renal cells [99] or in PC12 ceils [155]. However, no attempts
have been made to investigate a possible role for EGFR in mediating the H202-induced
phosphorylation of PKB in VSMC.
1.10 The insulïn-like growth factor type 1 receptor (IGF-1R)
The IGF-1R is a transmembrane protein tyrosine kinase that shares structural and
functional homology with the insulin receptor and is abundantly expressed in VSMC.
The mature receptor is a tetramer consisting of 2 extracellular a-chains and 2 intracellular
3-chains [156]. The 3-chains include an intracellular tyrosine kinase domain that is
believed to be essential for most of the receptor’s biologic effects [157]. Binding of IGF
1 or Insulin (at very high, unphysiological concentrations) induces the activation of PTK
domain of IGF-1R13 subunit which in tum activates the autophosphorylation of the
receptor (reviewed in [158]).
One of the earliest steps in signal transduction initiated by the IOF-1R is the
phosphorylation of adaptor/docking proteins such as insulin receptor substrate (WS-1 or
IRS-2), Shc and Grb2 [159;160]. WS-1, an important substrate for both the insulin and
the IGF-Ï receptor, contains multiple tyrosine phosphorylation sites that recognize and
bind SH2-containing signaling molecules, such as Grb2, Nck, the p85 subunit of P13-K
and the SH2 domain-containing tyrosine phosphatase-2 (SHP-2) [159]. 0f these, the
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binding of Grb2ISos to tyrosine-phosphorylated WS-1 activates Ras, which then
stimulates the Raf-1/MAPK cascade [161]. Shc can also interact directly with IGF-1R
[162]. After tyrosine phosphorylation of Shc, it recruits the Grb2/Sos complex and
activates the Ras/Raf-1/MEKIERK pathway [161] (Fig. 1.4). The activated IGF-1R also
triggers the P13-K and its downstream targets PKB and p7Os6k [163;164J (Fig. 1.5). The
Grb2-associated binding 1 (Gabl) can also function as an adaptor protein in mediating
IGF-W-induced signaling events [165] by interacting with Grb2, p85 subunit of P13-K
and SHP-2 [166]. As stated earlier, activation of MAPK pathway is critical for ceil
proliferation, whereas the P13-K pathway mediates the metabolic and antiapoptotic
response of IGF-1.
1.10.1 Transactivation of the IGF-1R
An important role for IGF-YR transactivation in triggenng AngII-induced
responses in VSMC was reported recently [167;168]. Pharmacological inhibition of IGF
1R kinase was found to markedly inhibit AngII-induced ERKI/2 phosphorylation in rat
V$MC [167] and P13-KIPKB activation in VSMC denved from the left anterior
descending coronary artery of porcine hearts [168]. It was also demonstrated that Angli
enhances the phosphorylation of the IGF-lRf3 subunit [16$] and that this phosphorylation
was prevented by AG53$ and AG1024, two selective inhibitors of IGF-1R tyrosine
kinase [169;170]. Interestingly, AngII-induced activation of MAPK appeared to be IGF
1R independent [168]. It should also be noted that the IGF-1R expression in VSMC is
regulated by several factors, including AngIl [171] and ROS [172]. Moreover, the up
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regulation of IOF-ÏR expression by Angil and basic fibrobÏast growth factor in VSMC
appears to be a critical determinant for their mitogenic effects [171].
Recently, Tabet et aï. have demonstrated that H202-induced ERK1/2 was blocked
by AG1024 in cultured VSMC from mesentenc arteries, suggesting a role for IGF-YR
transactivation in mediating the H202 response [103]. Whether H202 enhances the
tyrosine phosphorylation of IGF-1R or utilizes this receptor to activate other downstream
signaling components in VSMC has flot yet been investigated.
1.11 The ylatelet-derived growth factor receptor (PDGFR)
The PDGFR is a receptor tyrosine kinase expressed in many celi types including
VSMC [173] and its expression can be stimulated by AngIl [174]. It exists in two
isoforms: PDGFRŒ and PDGFRf3 that display affinity for the different isoforms of PDGF
family PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD. PDGFRŒ can be
activated by PDGF-AA, PDGF-AB, PDGF-BB and PDGF-CC, while PDGF-BB and
PDGF-DD bind and activate PDGFR (reviewed in [175]). Tissue culture and in vivo
mouse models studies have suggested that PDGFRŒ and PDGFRI3 activate distinct
signaling pathways. Downstream targets of the PDGFRF3 include ERK, PKB and smaïï G
proteins including Rho and Rac-1, which ultimately mediate PDGF-induced responses
such as celi cycle progression, migration, and survival (reviewed in [176]). Similar to
EGF, binding of PDGF to its receptor on the celi surface induces its dimenzation and
autophosphorylation of the tyrosine kinase domain which in tum recruits and activates
SH2 domain containing proteins such as Grb2, Src, p85 subunit of P13-K and
phospholipase C (PLCy). The Tyr75’ in the kinase domain of PDGFRf3 is the docking
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site for P13-K. Tyr74° is also important for the activation of P13-K by PDGFRf3 while
PDGF-stimulated PLCy signaling is dependent on the phosphorylation at the two sites
Tyr’°°9 and Tyr’°2’ (reviewed in [175]) (Fig. 1.4 and 1.5).
1.11.1 Transactivation of the PDGFR
Several studies have shown that PDGFR undergoes tyrosine phosphorylation in
response to AngIl [177] as well as ROS in different celi types such as MCF1OA [9$],
NIH3T3 fibroblasts [17$] and VSMC prepared from the thoracic aorta of Sprague
Dawley rats [146]. H202 was found to enhance the Tyr’°2’ phosphorylation of PDGFRf3
in a $rc- and PKOE-dependent manner [146]. On the other hand, unlike the EGFR
transactivation by ROS, PDGFR transactivation was shown to be independent of
metalloproteases effect [146]. An implication of PDGFR in ROS-induced activation of
MAPK pathway in VSMC derived from mesentenc arteries has been studied by using
AG1295, a selective inhibitor of PDGFR kinase, and it was found that this inhibitor
blocked only the phosphorylation of ERK1/2 but had no effect on p3$mapk
phosphorylation in response to H2O2 [103]. However, a similar involvement of PDGFR in
H202-induced phosphorylation of PKE bas flot been investigated to date.
1.12 The Src-family tyrosine kinases (SFKs)
The SFKs, a family of non-receptor tyrosine kinases, consists of nine structurally
related peptide members: c-Src, Fyn and Yes are widely expressed in most tissues,
whereas the others (Lck, Lyn, Hck, Fgr, Blk, Yrk) have a more restricted distribution
(reviewed in [179]). SFK are 52—62 kDa proteins composed of six distinct functional
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regions: the SH4 domain, the unique region, the SH3 domain, the SH2 domain, the
catalytic domain (SH1), and a short C-terminal tau containing a negative regulatory
tyrosine residue (Tyr3° in humans) (reviewed in [179]). The SH2 and SH3 domains are
important for molecular interactions that regulate Src catalytic activity, Src localization,
and recruitment of substrates, whereas the SH1 kinase domain contains
autophosphorylation site, which is important for regulation of its catalytic activity. This
site of phosphorylation corresponds to Tyr416 in mouse c-Src and Tyr419 in human’s,
which is flot phosphorylated in inactive wild type Src, but is constitutively
phosphorylated in activated Src (reviewed in [179]).
1.12.1 Activation of SFKs and its implication in signal transduction pathways
SFKs can be activated by various extra cellular stimuli, such as antigens, growth
factors, integnns [179], AngIl [180], ET-1 [181] and oxidative stress [99;100;182] in
vanous ceil types (Fig. 1.3). Among the SFKs, c-Src is the major isoform in the vascular
wall [183] and appears to be involved in contraction [184], proliferation [185], growth
[186] and cytoskeletal reorganization [187].
In the last few years, much attention has been given to the critical role of c-Src as
a mediator of GPCR- and H202-induced responses: transactivation of EGFR by GPCR
agonists [140;188;189] as well as by H202 [99] in different cell types were shown to be c
Src-dependent. Similarly, PDGFR transactivation by ROS seems to be Src-dependent in
VSMC [146] and in NIH3T3 fibroblasts [178].
Src is not only ïnvolved in GPCR-induced transactivation of RTK, but also in
tnggering the activation of MAPK and P13-KJPKB pathways in many celI types. Several
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studies reported that GPCR-mediated activation of the Ras/MAPK pathway involves Src
function [190-192]. Particularly in VSMC, AngII-induced activation of ERKÏ/2 pathway,
which is a potential contributor pathway to vascular remodeling, appears to be mediated
by Src [186]. Similarly, Src was shown to be a critical link in ET-1-induced ERK1/2
activation in rat myometnal cells [1811 and in ET-1-induced cardiomyocyte hypertrophy
[193].
Pharmacological approaches have suggested a role of c-Src in mediating H202-
induced ERK1/2 phosphorylation in mesenteric arteries VSMC [103], in CHO-W celis
[100] and in renal celis [99;154J. Moreover, c-Src-PTK activity appears to be required in
mediating H202-induced PKB phosphorylation in different ceil types such as CHO-W
[100], renal ceils [99] and in Rat-2 fibroblasts [98]. In contrast, diethylmaleate, which is
known to induce an increase in intracellular ROS levels, bas enhanced ERK1/2
phosphorylation in a Src-independent fashion in Rat-2 fibroblasts [98]. Conversely, a
recent report has shown that H202 markedly inactivates Src in vivo, but flot in vitro and
that a reduced phosphorylation of the tyrosine residue in the activation ioop is responsible
for the inactivation in vivo [194]. Therefore, it appears that H202 exerts both activation
and inhibitory effect on Src and triggers the responses of several agonists in a celi
specific manner and differently in vitro and in vivo.
1.13 The Proline rich tyrosine kinase 2 (Pyk2)
Pyk2 is a non-receptor tyrosine kinase, also known as related adhesion focal
tyrosine kinase (RAFFK) [195] or celi adhesion kinase beta (CAK) [196] or calcium
dependent tyrosine kinase [197]. It is a member of a family of tyrosine kinases that also
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includes p125 focal-adhesion kinase (FAK). Pyk2 and FAK are structurally related and
are both implicated as important integrating molecules in signal transduction cascades.
Pyk2 is expressed mainly in the nervous system, while FAK is widely expressed in
vanous tissues [198;199]. Pyk2 contains a central catalytic domain and two non-catalytic
domains, the N- and the C-terminal domains. The N-terminal domain contains a tyrosine
autophosphorylation site at Tyr402, which serves as a docking site for SFKs to bind via
their SH2 domains (reviewed in [199]). Studies have shown that Pyk2 plays a key role in
ceil signaling in many cell types, including rat pheochromocytoma PC12 cells
[155;190;19$], embryonic mouse fibroblasts [188], clone 9 (C9) hepatic celis [200] and
VSMC [32;201-205].
1.13.1 Activation of Pyk2 and its implication in signal transduction pathways
Pyk2 is activated by phosphorylation on tyrosine residues (Tyr402’ 580 and 881)
(reviewed in [199]) in a Ca2t and PKC-dependent fashion in PC12 [198] and VSMC
[201] in response to stimulation by GPCR agonists. Moreover, Pyk2 is known to interact
physically with SH2 domain containing molecules such as Src in PC12 cells
[190;198;206J, mouse embryonic fibroblasts [188], and VSMC [201]. This complex
formation between Pyk2 and Src is important in mediating GPCR-induced activation of
many downstream signaling, such as EGFR transactivation in mouse fibroblasts [18$]
and VSMC [207].
Several reports have shown that activated Pyk2 signals through the MAPK
family, such as ERK1/2 [19$], c-Jun amino-temiinal kinase (JNK) [190] or p3$mapk
[208] in PC12 cells. In VSMC, Rocic et al. have shown that Pyk2 acts as an upstream
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modulator of multiple signaling pathways involved in AngII-induced VSMC growth:
Angli ïnduced the formation of a complex between Pyk2 and the ERK1/2 regulators Shc
and Grb2 [204]. A role for Pyk2 in AngII-induced activation of P13-K and p70s6 kinase
has also been reported [204] (Fig. 1.3). Later on, the same group demonstrated by using
genetic approach the involvement of Pyk2 in AngII-induced protein synthesis in VSMC
[209]. Another vasoactive peptide, ET-1, was shown to induce tyrosine phosphorylation
of Pyk2 in cardiomyocytes [142;210] and rabbit carotid artery VSMC [211] as well as in
embryonic VSMC of rat aorta [32]. In cardiomyocytes, Pyk2 activation by ET-1 is
dependent on Src and PKC epsilon (PKC) [212], as well as Ca2 [142;210;212] and is
followed by ROS generation [210]. Kodama et al. have reported that Pyk2 was involved
in ET-1-induced ERK activation [142] and that Pyk2 activation as well as Pyk2/Src
association was required for ET-1-induced JNK activation in cardiomyocytes [213].
Furthermore, Pyk2 activation appears to be cntical in ET-1-induced cardiomyocyte
hypertrophy [210].
1.13.2 Activation of Pyk2 and its implication in cardiovascular diseases
Direct stimulation with exogenous F1202 was shown to enhance the tyrosine
phosphorylation of Pyk2 in many cell types, such as PC12 [155] and VSMC [203].
Recent studies have suggested that Pyk2 may represent a key signaling molecule
involved in vascular diseases because an upregulation in the basal phosphorylation of
Pyk2 in VSMC from SHR as compared with VSMC from WKY has been documented
recently. Moreover, AngII-enhanced phosphorylation of Pyk2 appeared to be more rapid
and more potent in SHR in these studies [214]. More recently, an involvement of Pyk2 in
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AngII-induced VSMC migration via JNK activation has also been reported, further
strengthening an important role for Pyk2 in VSMC functioning [215].
1.14 General Conclusion
In summary, oxidative stress is believed to be involved in vascular abnormalities,
such as hypertension and atherosclerosis. A number of studies have shown that ROS
activate key components of growth promoting and proliferative signaling pathways, such
as ERK1/2 and PKB in VSMC. An important role for receptor and non-receptor tyrosine
kinases in triggering some of the H202-evoked responses has been demonstrated in many
ceil types, including VSMC. Several studies carried out in VSMC isolated from different
vessel types have revealed that many tyrosine kinases act as upstream components in
H202-induced ERKI/2 phosphorylation. These tyrosine kinases include both growth
factor receptors and non-receptor tyrosine kinases. Most of these studies on ROS-induced
signaling in VSMC have focused on MAPK pathways and the intermediary role of EGFR
transactivation in this process (fig. 1.6). However, the potential contribution of other
growth factor receptors has flot been investigated in any detail and not much is known on
the mechanisms by which ROS activate PKB signaling in VSMC. Therefore, the studies
presented in this thesis were undertaken to elucidate a possible role for receptor and non
receptor tyrosine kinases on PKB, Pyk2 and ERKÏ/2 phosphorylation by H202 in VSMC.
These studies have used standard protocols of cellular and molecular biology such as ceil
culture, immunoprecipitation and western blotting.
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Figure 1.6: Scheme summarizing the major ROS-induced signalïng pathways that
are responsible of their pathological effects. High levels of ROS or oxidative stress, by
inhibiting protein tyrosine phosphatases and activating thereby protein tyrosine kinases,
trigger the activation of two major signaling pathways, the MAPK and the P13-KIPKB
pathway in a Ca2-dependent fashion. Aberrant activation of these pathways enhances
protein synthesis, celi growth, hypertrophy, migration as well as survival responses,
which are critical events in vascular remodeling, associated with cardiovascular
disorders. Increased Ca2 levels may also have a direct effect on vascular disorder by
modifying the contractile response of the vascular smooth muscle cells.
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ABSTRACT
Evidence accumulated in recent years lias revealed a potential role of reactive oxygen
species (ROS) in the pathophysiology of cardiovascular diseases. However, the precise
mechanisms by which ROS contribute to the development of these diseases are flot fuÏly
identified. Previous work from our laboratory lias indicated tliat exogenous liydrogen
peroxide (H202) activates several signaling protein kinases, such as extracellular signal
regulated kinasel and 2 (ERK1/2) and protein kinase B (PKB) in AlO vascular smootli
muscle cells (VSMC). However, the upstream elements responsible for this activation
remain to be clarified. Although an important role of epidermal growth factor receptor
(EGFR) protein tyrosine kinase (PTK) in H202-induced ERK1/2 signaling lias been
suggested, tlie contribution of this PTK or other receptor or non-receptor PTK in PKB
activation is not well defined in VSMC. In tlie present study, we liave investigated tlie
role of receptor and Src-family-PTKs in H202-induced PKB pliosphorylation using
pliarmacological inhibitors. AG1478, a specific inliibitor of EGFR, failed to attenuate tlie
H202-induced increase in PKB Ser473 phospliorylation, whereas AG1024, an inhibitor of
insulin-like growth factor typel receptor (IGF-1R)-PTK, almost completely blocked tliis
response. H202 treatment also enlianced tyrosine pliospliorylation of the IGF-lRf3
subunit, wliich was significantly inliibited by AG1024 pretreatment of cells. Furtliermore,
pharmacological inliibition of Src by PP2 (4-amino-5-(4-clilorophenyl)-7-(t-
butyl)pyrazole[3,4-d] pyrimidine) decreased PKB pliospliorylation. Moreover, H202-
induced PKB pliosphorylation was associated witli increased tyrosine phospliorylation of
c-Src and Pyk2 in an AG1024 and PP2-inliibitable manner. In conclusion, tliese data
provide evidence for the contribution of IGF-1R-PTK in initiating H202-evoked PKB
pliosphorylation in AlO VSMC witli an intermediary role of c-Src and Pyk2 in tliis
process.
Key words: Protein kinase B, Hydrogen peroxide, Growth factor receptor protein
tyrosine kinase, Src-family protein tyrosine kinase, Proline-ricli tyrosine kinase, Vascular
smootli muscle cells.
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Introduction
Reactive oxygen species (ROS) are believed to play a critical role in the pathophysiology
of cardiovascular diseases such as hypertension, atherosclerosis and restenosis after
angioplasty (Dhalla et al. 2000; Droge 2002; Fortuno et al. 2005; Pollock and Pollock
2005), as well as in vascular complications associated with diabetes (Ceriello and Motz
2004). Two key vasoactive peptides, angiotensin II (Angil) and endothelin-1 (ET-1), that
are also important growth factors for vascular smooth muscle cells (VSMC) (Battistinï et
al. 1993; Daou and Srivastava 2004; Touyz et al. 2004), and are believed to contribute to
vascular diseases (Touyz and Schiffrin 2003; Pollock and Pollock 2005; Sainani et al.
2005; Sun 2005; Tostes, and Muscara 2005) mediate their vasoactive responses through
ROS generation (Zafan et al. 199$; Fei et al. 2000; Wedgwood. et al. 2001; Daou and
Srivastava 2004). An important source of ROS in VSMC is NAD(P)H oxidase, which
catalyzes the generation of superoxide anion (Oj) from molecular oxygen (02) (Ushio
Fukai et al. 1996; Touyz et al. 2002; Niemiec and Zak 2005). 02 is a relatively unstable
molecule and is rapidly converted by a dismutation reaction to hydrogen peroxide (H202)
(Bovens and Chance 1973).
Recent studies have demonstrated an exaggerated production of ROS such as 02 and
H202 in many animal models of hypertension (Guo et al. 2003; Li et al. 2003; Sedeek et
al. 2003). Moreover, a direct role of H202 in AngII-induced vasculature hypertrophy has
been suggested recently (Zhang et al. 2005). Exogenous H202 activates several signaling
protein kinases, such as mitogen-activated protein kinases (MAPK) and protein kinase B
(PKB) (Wang et al. 2000; Blanc et al. 2003; Blanc et al. 2004; Mehdi et al. 2004; Zhuang
and Schnellmann 2004), which have been proposed to play key roles in mediating the
hypertrophie response in VSMC (Daigle et al. 2004). Although the precise mechanism
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and intermediary steps by which H202 activates these signaling pathways remain poorly
characterized, the involvement of receptor and non-receptor protein tyrosine kinases
(PTK) as potential transducers of H202-evoked responses lias been suggested (Frank et
al. 2003; Melidi et al. 2004; Zhuang and Sclinellmann 2004; Purdom and Clien 2005;
Tabet et al. 2005). Specifically, a prominent contribution of epidermal growth factor
receptor (EGFR) transactivation in mediating H202-induced activation of extracellular
signal regulated kinase 1 and 2 (ERK1/2) lias been documented in many ceil types
(Zhuang and Schnellmann 2004; Purdom and Chen 2005). However, a precise role of
growtli factor receptor and Src-family PTKs in mediating H202-induced effects on PKB
signaling in VSMC bas not yet been elucidated.
PKB, also known as Akt, exists as 3 isoforms, a, f3 and y (Aktl, Akt2 and Akt3,
respectively); eacli isoform possesses an amino-terminal pleckstrin liomology (PH)
domain, a kinase domain and a carboxy-terminal regulatory domain. PKB is rapidly
activated in response to insulin (Farese et al. 2005; van der Heide et al. 2005), AngIl
(Saward and Zahradka 1997), ET-1 (Daou and Srivastava 2004), and many other growtli
factors (Duan et al. 2000; Cenni et al. 2003; Dolloff et al. 2005; Markadieu et al. 2005;
Zaka et al. 2005) in a pliospliatidylinositol 3-kinase (PI3K)-dependent manner. PI3K is a
lipid kinase that promotes the generation of 3’-phosphoinositides, such as phosphatidyl
inositol 3,4,5 triphosphate (PW3). PW3 binds to the PH domain of PKB and recruits it to
the plasma membrane for phosphorylation by phosplioinositide-dependent kinases 1
(PDK-1) and 2 (PDK-2). PDK-1 phosphorylates PKB at threonine 308 in the catalytic
domain whereas putative PDK-2 phosphorylates it at serine 473 in the C-terminal
regulatory domain of PKB (Whiteman et al. 2002). Activated PKB phosphorylates
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several downstream substrates, such as glycogen synthase kinase-3f3, Forkhead
transcription factor, Bcl-2-associated death, 1kB kinase, mammalian target of rapamycin,
Mdm2, Caspase 9 and endothelial nitnc oxide synthase (Whiteman et al. 2002; Song et
al. 2005). Phosphorylated forms of these substrates regulate diverse cellular functions,
such as glucose transport, celi growth, gene expression, celi survival and death as well as
protein synthesis (Saward and Zahradka 1997; Datta et al. 1999).
In the present study, by using a series of pharmacological and celi biological approaches,
we have examined the involvement of receptor and non-receptor PTKs as potential
upstream modulators of H202-induced PKB phosphorylation and activation in AlO
VSMC. AlO VSMC, denved from the rat embryonic thoracic aorta, which exhibit
characteristics similar to those of normal VSMC (Kimes and Brandt 1976) and have been
extensively accepted as a model for the investigation of vascular cellular processes
(Hashim et al. 2004, Daou and Snvastava 2004, Chen et al. 2006).
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Materials and Methods
Materiaïs
H202 was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Phospho
specific antibodies to PKB (Ser473) and Pyk2 (Tyr402), total PKB antibody and anti
rabbit secondary antibody were from New England BioLabs (Beverly, MA, U.S.A.).
Phospho-specific c-Src antibody (Tyr418) was from Biosource (Camarillo, CA, U.S.A.).
Antiphosphotyrosine antibody (PY99), total c-Src antibody, total insulin-like growth
factor receptor-ibeta (IGF-1R13) subunit antibody and anti-mouse secondary antibody
were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Total Pyk2 antibody was
from Upstate Biotechnology (Lake Placid, NY, U.S.A.). Epidermal growth factor (EGF)
and ail pharmacological inhibitors were from Calbïochem (San Diego, CA, U.S.A.).
Human IGF-1 was from PeproTech Inc. (Rocky Hill, NJ, U.S.A.). Ail cell culture
materials were from Invitrogen Corp. (Grand Island, NY, U.S.A.). Protein A Sepharose
beads and enhanced chemiluminescence (ECL) detection kits were from Amersham
Pharmacia Biotech (Baie d’Urfé, Quebec, Canada).
Ce!! Culture
AlO VSMC, obtained from the American Type Culture Collection (Manassas, VA,
U.S.A.), were maintained in Dulbecco Modified Eagle Medium (DMEM) containing
10% of fetal bovine serum and 1% of penicillin + streptomycin in a humidified
atmosphere of 5% C02 exchange at 37°C as described earlier (Srivastava and Pandey
2000). They were passaged twice a week by harvesting with TrypsinIEDTA.
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Stimulation of VSMC aïtd Immunobtotting
VSMC were grown to 80-90% confluence in 60-mm culture plates and incubated in
serum-free DMEM for 5 hours prior to the experiments. CeIls subjected to various
experimental treatments were washed twice with ice-cold phosphate-buffered saline
(PBS) and scraped on ice in lysis buffer (10 mM Na4P2O7, 25 mM NaC1, 10 mlvi NaF, 2
mM benzamidine, 25 mM Tris-HC1 pH 7.4, 2 mlvi EGTA, 2 mlvi EDTA, 1 mM Na
molybdate, 1 mlvi Na orthovanadate, 1 mlvi phenylmethylsulfonyl fluoride, 10 ig/mL
aprotinin, 10 WmL leupeptin, 1% (vol/vol) Nonidet P-40 and 0.1% (vol/vol) sodium
dodecyl sulfate (SDS)). The lysates were clarified by centrifugation at 4°C to remove
insoluble materials. Clarified lysates containing equal amounts of protein, as detemiined
by Bradford’s method, were separated by 7.5% SDS—polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidine difluoride (PVDF) membranes. The
membranes were blocked for 1 hour with PBS-Tween 20 containing 5% non-fat dry milk
at room temperature. The blots were incubated ovemight with respective pnmary
antibodies at 4°C and gentle shaking. The following day, they were incubated with
secondary antibodies (horseradish peroxidase-conjugated anti-rabbit or anti-mouse) at
room temperature. The antigen-antibody complex was visualized by the ECL method
(Mehdi et al. 2004). The intensity of the protein hands was quantified by Nifi Image
software (Daou and Srivastava 2004).
Immunoprecipitation
CelIs were grown to 80-90% confluence in 100-mm culture plates and incubated in
serum-free DMEM for 5 hours prior to the experiments. Stimulation and cell lysis was
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performed as descnbed above. The clarified lysates, normalized to contain equal amounts
of protein (500 were immunoprecipitated ovemight with 2 g of PY99 antibody at
4°C, followed by incubation with protein A Sepharose for an additional 2 hours.
Immunoprecipitated phosphotyrosine proteins were collected by centrifugation, then
washed once with PBS and twice with lysis buffer. The phosphotyrosine protein
immunoprecipitates were separated by 7.5% SDS-PAGE, transferred to PVDF
membranes and incubated with primary antibody (for IGF-lRf3). Proteins were detected
by a horseradish peroxidase-conjugated secondary antibody and visualized with an ECL
detection kit (Mehdi et al. 2004). The intensity of the protein bands was quantified by
NIH Image software (Daou and Srivastava 2004).
Statistics
Statistical analysis was performed by one-way, repeated measures analysis of variance
(ANOVA), followed by a Newman-Keuls posttest. Ail data are reported as means ± SE.
The differences between means were considered significant at P< 0.05.
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Resuits
AG]024 but not AG]478 inhibits H202-induced PKB phosphoïylation
Several studies have reported on the role of EGFR transactivation in H202-induced
phosphorylation of MAPKs, such as ERKY/2 and p38 MAPK, in vanous celi types,
including VSMC (Purdom and Chen 2005; Tabet et al. 2005). Therefore, we first
examined if EGFR-PTK played a similar role in H202-induced PKB phosphorylation in
AlO VSMC. For this purpose, we used AG1478, an ATP-binding site inhibitor of EGFR
PTK (Levitzld and Gazit 1995). Treatment of AlO celis wïth 10 LM of AG1478 for 30
minutes failed to inhibit H202-induced PKB phosphorylation as assessed by a phospho
specific Ser473 antibody (Fig. lA). However, under these conditions, as expected, EGF
induced PKB phosphorylation was almost completely attenuated in AG1478-pretreated
celis (Fig. lA). In contrast, IGF-1-induced PKB phosphorylation was not affected by
AG 147$ pretreatment.
It was reported recently that the stimulatory effect of Angli on PI3KJPKB signaling in
primary cultures of smooth muscle celis from the left antenor descending coronary artery
of porcine hearts ïs mediated through IGF-1R transactivation (Zahradka et al. 2004).
Therefore, we wished to investigate if IGF-1R contnbutes to H202-induced PKB
phosphorylation in AlO VSMC. For these experiments, we utilized AG1024, a highly
selective inhibitor of IGF-1R-PTK (Parrizas et al. 1997). As seen in Figure lB, AG1024
treatment of AlO celis almost completely blocked H202-induced PKB phosphorylation. A
similar inhibitory effect of AG1024 on IGF-1-induced PKB phosphorylation was
observed, whereas this compound had no effect on EGF-stimulated PKB phosphorylation
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(Fig. lB). These resuits suggested a role of IGF-1R-PTK in enhanced PKB
phosphorylation in response to H202 in AlO celis.
FI2 02 increases tyrosine phosphoîylation ofIGF-]Rfl
Since tyrosine phosphorylation of the IGF-lRf3 subunit is essential for its intrinsic PTK
activity, we next evaluated if H202 treatment enhances the level of its tyrosine
phosphorylation. This was achieved by stimulating AlO ceils with H202 for 10 minutes or
with IGF-1 for 5 minutes. Ccli lysates were subjected to immunoprecipitation with
phosphotyrosine-specific antibody, followed by immunoblotting with the anti-IGF-1R3
subunit antibody. As illustrated in Figure 2, both H202 and IGF-1 induced an increase in
the tyrosine phosphorylation of IGF-lRf3, and AG1024 markedly inhibited this response
(Fig. 2).
H202-induced PKB pÏzosphoiylation requires c-Src activity
Several reports have suggested a role for the Src famiiy of non-receptor PTKs in
triggering some signaling events induced by ROS (Mehdi et al. 2004; Tabet et al. 2005)
and Angli (Shah and Catt 2002; Touyz et ai. 2004). Therefore, we wcre interested to
investigate the possible involvement of these kinases in H202-induced PKB
phosphorylation in AlO VSMC. As illustrated in Figure 3, pretreatment of ceiis with PP2
(4-amïno-5-(4-chlorophenyl)-7-(t-butyi)pyrazole [3,4-d] pyrimidine), a seiective inhibitor
of Src famiiy PTK (Hanke et al. 1996), pnor to stimulation with H202, markediy
attenuated PKB phosphorylation in response to H202. In contrast, PP3 (4-amino-7-
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phenylpyrazol [3,4-d] pynmidine), an inactive analogue of PP2, had no effect on H202-
induced PKB phosphorylation under these conditions.
H202-induced c-Src phosphorylation requires PTK activity ofIGF-]R
Src-PTKs are activated subsequent to phosphorylation of a conserved tyrosine residue
(Tyr418 in human Src) located in its activation ioop (Thomas and Brugge 1997).
Therefore, further proof for the involvement of Src-PTK in H202-induced effects was
obtained by directly detennining changes in the phosphorylation status of Tyr4l $ in
H202-treated AlO celis. As seen in Figure 4, H202 increased Tyr4l$ phosphorylation in
these ceils. To further elucidate any cross-talk between IGF-1R-PTK and Src-PTK, we
studied the effect of AG1024 on c-Src phosphorylation. As shown in Figure 4,
pretreatment with AG1024, but not AG1478, markedly inhibited H202-induced
phosphorylation of c-Src, suggesting that IGF-ÏR-PTK is necessary for c-Src activation
byH2O2inA1OVSMC.
H202-induced Pyk2 phosphorytation depends on c-Src and IGF-]R but not 012 EGFR
activity
Recent investigations have indicated that Pyk2, a cytosolic Ca2tdependent proline-rich
tyrosine kinase (Lev et al. 1995), plays a role in AngII-induced PI3KJPKB signaling in
VSMC (Rocic et al. 2001). Moreover, Pyk2 is activated by H202 (Frank et al. 2000), and
is known to associate with c-Src-PTK (Dikic et al. 1996; Andreev et al. 2001). Therefore,
we wished to examine if H202-induced PKB phosphorylation was linked with Pyk2
phosphorylation and if Src-PTK was involved in this response in AlO celis. As depicted
in Figure 5, 11202 treatment enhanced the tyrosine phosphorylation of Pyk2 that was
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completely suppressed by PP2, whereas PP3 had no effect on this phosphorylation (Fig.
5A). Next, we examined the possible involvement of IGF-IR-PTK in Pyk2
phosphorylation by H202. As revealed in Figure 5B, AG1024 pretreatment markedly
decreased Pyk2 phosphorylation, but AG1478 had no effect. These data suggested that c
Src and IGF-1R but not EGFR-PTK are required for Pyk2 phosphorylation by H202 in
AlO ceils.
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Discussion
In this study, we have demonstrated that PKB phosphorylation in AlO VSMC, in
response to exogenous H202, is mediated pnmarily through the IGF-IR-PTK-dependent
pathway. Although a partial contribution of IGF-1R-PTK in Angli- and H202-induced
ERK1/2 phosphorylation has been documented (Touyz et al. 2003; Cruzado et al. 2005;
Tabet et al. 2005), to the best of our knowledge, the data presented here are the first to
identify a role for IGF-1R-PTK in H202-induced PKB phosphorylation in VSMC.
Several investigations in different celi types have revealed that EGFR-PTK serves as a
mediator of H202-induced activation of MAPK pathways (Zhuang and Schnellmann
2004; Purdom and Chen 2005; Tabet et aI. 2005). However, failure of AG1478, the
specific inhibitor of EGFR-PTK, to block H202-enhanced PKB phosphorylation while
inhibiting EGF-induced PKB phosphorylation, indicated that EGFR-PTK does not
participate in PKB activation by H202 in AlO celis. This notion is further supported by
recent expenments showing that H202-induced PKB phosphorylation is independent of
EGFR-PTK activity in renal ceils (Zhuang and Schnellmann 2004). In contrast to these
studies, H202-induced activation of PKB was found to be dependent on EGFR-PTK in
HeLa ceils (Wang et al. 2000). The reason for these discrepancies is flot clear but it may
be attnbuted to celi-specific differences in response to H202 or the differential expression
level of EGFR in various celis.
The fact that H202 treatment induced an increase in tyrosine phosphorylation of the IGF
1R13 subunit lends further support to a roTe for IGF-1R-PTK activation in triggering H202
responses in AlO ceils. A similar increment of IGF-1R tyrosine phosphorylation in
response to AngIl has been demonstrated in pnmary cultures of smooth muscle celis
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denved from the coronary artery of porcine hearts (Zahradka et ai. 2004). These authors
also reported that AngII-ïnduced phosphorylation of the p85 subunit of PI3K and of
p7Os6k, a downstream substrate of PI3K, was suppressed by IGF-ÏR-PTK inhibitors
(Zahradka et al. 2004). Thus, it appears that H202 and Angil, that signais through the
generation of H202 primarily utilize IGF-1R-PTK activation as a mechanism to tum on
the PI3K!PKB signaling pathway.
We aiso provided evidence that, along with IGF-1R-PTK, c-Src activation is required for
H202-induced PKB phosphorylation in VSMC. Similar observations were reported
previousiy in Chinese hamster ovary (CHO) ceiis (Mehdi et al. 2004), in rat-2 fibroblasts
(Esposito et al. 2003) and in renal ceils (Zhuang and Schnellmann 2004) where PP2 was
found to decrease H202-induced PKB phosphorylation. Our resuits, showing that c-Src
phosphorylation was aimost compietely blocked by inhibition of IGF-1R-PTK, suggested
that F1202 might activate c-Src through an TGF-ÏR-dependent pathway. Supporting these
observations, recent studies have established that IGF-1 treatment increased c-Src
phosphorylation in 3T3-L1 preadipocytes (Sekimoto and Boney 2003; Sekimoto et al.
2005). It thus appears that one of the consequences of IGF-1R activation is the
enhancement of c-Src activity.
Pyk2, a target of H202, is known to interact physicaliy with c-Src (Dikic et al. 1996;
Sabn et al. 1998; Andreev et al. 2001; Lakkakorpi et al., 2003; Park et al. 2004), and lias
been implicated as an upstream reguiator of PI3K!PKB signaling in response to Angli in
VSMC (Rocic and Lucchesi 2001; Rocic et al. 2001; Rocic et al. 2003). It is thus possibie
that Pyk2 may have a similar role in H202-induced PKB phosphoryiation in AlO VSMC.
This notion is supported by observations showing that phamiacoiogical inhibition of Src
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and IGF-1R-PTKs blocked flot only PKB phosphorylation, but also Tyr402
phosphorylation of Pyk2. A recent report that overexpression of a dominant form of Pyk2
reduced PKB phosphorylation induced by H202 in PC12 celis lends additional support for
a role of Pyk2 as a mediator of PKB activation (Banno et aI. 2005).
Several laboratones have determined that the Phosphatase and Tensin homolog deleted
on chromosome ten (PTEN), which catalyzes PIP3 dephosphorylation, is a direct target of
H202 and becomes inactivated by oxidation of Cys-124 in its catalytic site subsequent to
H202 treatment (Lee et al. 2002). Inactivation of PTEN, which resuits in an increase of
PIF3 levels, has been attributed to PKB activation in response to several agents known to
generate ROS (Leslie et al. 2003; Kwon et al. 2004; Seo et aI. 2005). However, our
earlier studies, showing that H202 treatment enhanced PI3K activity in CHO celis
overexpressing human insulin receptor and that Wortmannin, an inhibitor of PI3K,
suppressed H202-induced PKB phosphorylation (Mehdi et al. 2004), indicate that
stimulation of PI3K by H202 also plays an important part in this response. Moreover, our
observations that AG1024 blocked H202-induced PKB phosphorylation further suggested
that PTEN inhibition alone cannot contribute to this effect but also requires IGF-1R-PTK
activation. The precise mechanism by which H202 activates IGF-1R-PTK in AlO celis is
stili unclear. However, in view of the ability of H202 to inhibit protein tyrosine
phosphatases (PTPases), such as PTP1B (Lee et al. 199$) and SHP-2 (Meng et al. 2002),
it may be postulated that H202 treatment can shïft the equilibnum of the phosphorylatïon
dephosphorylation cycle, culminating in a net increase of the tyrosine phosphorylation of
IGF-1R andlor other proteins, which may tngger the IGF-1R-PTK signaling pathway
(Fig. 6).
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In summary, the data presented here demonstrate that H202 enhances PKB
phosphorylation in AlO VSMC. PKB phosphorylation by H202 occurs in an IGF-1R- and
Src-PTK-dependent manner with a potential intermediary role of Pyk2 (Fig. 6). Since
PKB is a critical component of ceil survival, hypertrophic and proliferative pathways, it
may be speculated that aberrant activation of PKB and its downstream components by
ROS might contribute to the pathophysiology of vascular abnormallties.
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Figure legends
Figure 1: Effect of AG1478 and AG1024 on 11202-induced PKB phosphorylation in
AlO VSMC. Confluent, serum-starved AlO ceils were pretreated with (+) or without (-)
10 tM AG147$ (A) or 1 tM AG1024 (B) for 30 minutes, followed by stimulation in the
absence (C) or presence of 500 tM H20 for 10 minutes, 10 nM EGF or 1 ng/mL IGF-l
for 5 minutes. The celis were lysed, and equal amounts of protein were separated on 7.5%
SDS-PAGE. PKB phosphorylation was detected by immunoblotting wïth phospho
specific Ser473 PKB antibody (top panel of each section). Blots were also analyzed for
total PKB (middle panel). The bottom panels represent average data quantified by
densitometric scanning of the immunoblots shown in the top panels. Values are the
means ± SE of at least 3 independent experiments and are expressed as percent
phosphorylation where phosphorylation observed with either H202, EGF or IGF-1 alone
is defined as 100%. (A) ‘P<0.001 vs control (C), #p<J vs control (C), §p<• vs
control (C), P<0.001 vs EGF. (B) *P<0.00l vs control (C), #p<fl vs control (C),
P<0.001 vs control (C), P<0.001 vs H709, P<0.001 vs IGF-1.
Figure 2: Effect of H202 on IGF-lRp tyrosine phosphorylation in AlO VSMC.
Confluent, serum-starved AlO celis were pretreated with (+) or without (-) 1 jM AG1024
for 30 minutes, followed by stimulation in the absence (C) or presence of 500 M F1202
for 10 minutes or 1 ng/mL IGF-1 for 5 minutes. The ceils were lysed, and equal amounts
of protein from the clarified lysates were subjected to immunoprecipitation (W) with
antiphosphotyrosine (PY99) antibody. The immunoprecipitates were immunoblotted with
an antibody to the IGF-1R13 subunit (top panel). Whole lysates were also analyzed for the
total IGF-lRf3 subunit (middle panel). The bottom panel represents average data
quantified by densitometnc scanning of the immunoblots shown in the top panel. Values
are the means ± SE of at least 3 independent expenments and are expressed as percent
phosphorylation where phosphorylation observed with either H202 or IGF-1 alone is
defined as 100%. *p<JJ vs control (C), #P<0.01 vs control (C), TP<0.01 vs H207,
tP<0.01 vsIGF-1.
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Figure 3: Effect of PP2 on H202-induced PKB phosphorylation in AlO VSMC.
Confluent, serum-starved AlO ceils were pretreated with (+) or without t-) 10 M PP2 or
its inactive analogue PP3 for 30 minutes, followed by stimulation in the absence (C) or
presence of 500 iM H202 for 10 minutes. The ceils were lysed, and equal amounts of
protein were separated on 7.5% SDS-PAGE. PKB phosphorylation was detected by
immunoblotting with phospho-specific Ser473 PKB antibody (top panel). Blots were also
analyzed for total PKB (middle panel). The bottom panel represents average data
quantified by densitometric scanning of the immunoblots shown in the top panel. Values
are the means ± SE of at least 3 independent experiments and are expressed as percent
phosphorylation where phosphorylation observed with H202 is defined as 100%.
*P<0 001 vs control (C), tP.<0.001 vs H202.
Figure 4: Effect of AG1478 and AG1024 on H202-induced c-Src phosphorylation in
AlO VSMC. Confluent, serum-starved AlO cells were pretreated with (+) or without (-)
10 iiM AG1478 or 1 tM AG1024 for 30 minutes, followed by stimulation in the absence
(C) or presence of 500 iM H202 for 10 minutes. The celis were lysed, and equal amounts
of protein were separated on 7.5% SDS-PAGE, and c-Src phosphorylation was detected
by immunoblotting with phospho-specific Tyr418 c-Src antibody (top panel). Blots were
also analyzed for total c—Src (middle panel). The bottom panel represents average data
quantified by densitometric scanning of the immunoblots shown in the top panel. Values
are the means ± SE of at least 3 independent expenments and are expressed as percentage
phosphorylation where phosphorylation observed with H202 is defined as 100%.
vs control (C), P<0.001 vs H202.
Figure 5: Effect of AG1478, AG1024 and PP2 on H202-induced Pyk2
phosphorylation. Confluent, serum-starved AlO ceils were pretreated: (A) with (+) or
without (-) 10 AG1478 or 1 M AG1024 for 30 minutes, or (B) 10 iM PP2 or its
inactive analogue PP3 for 30 minutes, followed by stimulation in the absence (C) or
presence of 500 iM H202 for 10 minutes. The cells were lysed, and equal amounts of
protein were separated by 7.5% SDS-PAGE. Pyk2 phosphorylation was detected by
immunoblotting with phospho-specific Tyr402 Pyk2 antibody (top panel of each section).
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Blots were also analyzed for total Pyk2 (middle panel). The bottom panel represents
average data quantified by densitometric scanning of immunoblots shown in the top
panel. Values are the means ± SE of at least 3 independent expenments and are expressed
as percent phosphorylation where phosphorylation observed with H202 alone is defined
as 100%. (A)*P<0.01 vs control(C) , P<O.Ol vs H202. (B) *p<JJ vs control (C),
tP<005 vs H202.
Figure 6: Schematic model showing the signaling cascade induced by 11202 in AlO
VSMC. H202 enhances tyrosine phosphorylation of the IGF-1R3 subunit which is
blocked by AG1024. IGF-1R activation is necessary for H202-induced phosphorylation
of PKB, c-Src and Pyk2 because ail these events are blocked by AG1024. Src appears to
be upstream of Pyk2 and PKB, since its pharmacological inhibition by PP2 decreases
both Pyk2 and PKB phosphorylation. Pyk2 may be acting upstream of PKB via a yet
undefined pathway. The mechanism by which H202 stimulates IGF-ÏRF3 phosphorylation
remains obscure, but the ability of H202 to inhibit PTPases might contnbute to this effect.
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CHAPTER 3
GENERAL DISCUSSION
71
ROS generated in the vasculature are recognized as important second messenger
molecules at physiological concentrations [2161. However, a large body of evidence
supports an important role for high levels of ROS (oxidative stress) in cardiovascular
disorders including hypertension, atherosclerosis, vascular injury and diabetes. This is
due, in part, to 02 excess and decreased bioavailability of NO and to ROS-mediated
cardiovascular remodeling [17;75;217]. Both O2 and H202 were shown to increase
vascular contractility, stimulate VSMC growth and induce inflammatory responses
[39;218-221]. In this context, several studies have investigated the possible protective
effect of antioxidants. Since ROS mediate their effects through redox-sensitive signaling
pathways, a better knowledge of these pathways would be necessary for developing
specific therapeutic agents directed against critical components of ROS signaling systems
implicated in different pathologies.
Over the last few years, studies have identified many redox-sensitive pathways,
including MAPK and P13-KIPKB signaling systems in many ccli types particularly in
VSMC isolated from different artery beds [11;102;104;12$;222]. Activation of these
pathways has been linked to ce!! growth, proliferation, hypertrophy and surviva!, which
are critica! events for vascular remode!ing. Since vascular diseases are often associated
with excessive ce!l growth and pro!iferation, there is a lot of interest to understand the
precise mechanisms by which ROS induce the activation of these pathways.
Using H202 as a mimicker of ROS, severai studies have suggested a role for
receptor and non-receptor PTK as well as Ca2 and PKC in H202-induced activation of
MAPK and P13-K!PKB pathways. Majority of these in vitro studies have used high
micromo!ar concentrations of H202. These concentrations can be considered as
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“pathological” [223-226] because “normal” physiological concentration of H202 in the
plasma of normotensive humans have been reported to be in low micromolar (3 iM)
[227]. However, the effect of these Iow H202 concentrations on signaling pathways lias
flot been examined in detail in cardiovascular system. This may be due to the possibility
that acute treatment with low H202 concentration (3-5 tM) does flot show detectable
change in the activation/phosphorylation of the signaling components. For example,
Blanc et al. have shown that both Ca2 chelators and the calmodulin inhibitor
Fluphenazine markedly decreased H202-induced ERK1/2, p38mapk and PKE
phosphorylation in AlO VSMC celi une [102]. More recently, by using pharmacological
inhibitors, Tabet el al. have reported that H202-induced ERK1/2 phosphorylation was
regulated by both receptor- and non-receptor-PTK, whereas p38mapk phosphorylation
was regulated exclusively by non-receptor-PTK in primary cultures of VSMC from rat
mesenteric arteries [103]. Whether H202-induced PKB phosphorylation was tyrosine
kinase dependent in VSMC has not yet been investigated. Therefore, these studies were
undertaken to investigate a role for receptor- and non-receptor-PTK in H202-induced
PKB and ERK1/2 phosphorylation.
By using pharmacological inhibitors, we have shown that H202-induced PKB and
ERK1/2 phosphorylation was dependent on IGF-1R, since pretreatment of the ceils with
A01024, a specific inhibitor of IGF-1R kinase, abrogated the H202-induced PKB
(Chapter 2) as well as ERK1I2 phosphorylation (Fig. 3.7).
Further proof for the involvement of the IOF-ÏR in this response was provided by
the resuits showing that H202 enhanced the tyrosine phosphorylation of the IGF-1R f3-
subunit in AlO VSMC (Chapter 2). A role for IGF-1R transactivation in AngII-induced
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activation of P13-KIPKB pathway has been observed in porcine coronary VSMC [1681.
Thus, it appears that both exogenous H202 and Angil, which is an inducer of ROS
generation, mainly utilize IGF-ÏR to trigger the activation of P13-KIPKB pathway in
VSMC.
Several studies have shown that EGFR-PTK plays a role in tnggenng the H202-
induced MAPK activation in renal cells [99], cardiomyocytes and cardiac fibroblasts
[101] as well as primary cultures of VSMC [103;145]. Moreover, H202 is able to enhance
tyrosine phosphorylation of EGFR in VSMC [129;145;146]. On the other hand, H202-
induced PKB activation has been shown to be EGFR-dependent in HeLa cells [127], but
not in renal celis [99] or PC12 cells [155]. Our data suggests that EGFR transactivation
does not participate in neither PKB nor ERK1/2 activation by H2O2 in AlO VSMC, since
AG1478, the specific inhibitor of EGFR kinase, had no inhibitory effect on PKB
(Chapter 2) or ERKI/2 phosphorylation (Fig. 3.7) in response to H202. The reason for
this conflicting data is unknown, but could be related to celi-specific responses of H202.
The PDGFR bas been shown to undergo tyrosine phosphorylation in response to
H202 in rat aortic VSMC [146] and appears to be implicated in H202-induced ERKY/2
phosphorylation in VSMC derived from mesenteric artenes of SHR and WKY rats [103].
Therefore, we tested the possible implication of the PDGFR-PTK in H202-induced PKB
and ERK1/2 phosphorylation in AlO ceils by using AG1295, the specific inhibitor of
PDGFR-PTK [228]. Pretreatment of celis with AG1295, failed to inhibit the H202-
induced PKB (fig. 3.8(A)) and ERK1/2 phosphorylation (Fig. 3.8(B)), whereas it
blocked completely the PDGF-evoked effect. The reason for the discrepancy between our
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studies and that of others is unclear. However, it could be due to the type of VSMC used,
which might affect the responsiveness to the stimulant.
We also provided evidence that flot only receptor-PTK could play important roles
in mediating H202 responses, but also non-receptor-PTK such as Src, contributes to this
effect. By usïng PP2 as a specific inhibitor for c-Src, previous work from our laboratory
has shown that H202-induced ERK1/2 and PKB phosphorylation were Src-dependent in
CHO cells [100]. Similarly, PP2 significantly inhibited H202-stimulated ERK1/2 and
p38mapk phosphorylation in VSMC [103] as well as PKB activation in Rat-2 fibroblasts
[98] and in renal celis [99]. Our data was the first to demonstrate a role for c-Src as an
upstream regulator of PKB activation in response to H202 in VSMC (Chapter 2).
Moreover, we have also shown that H202 enhanced the phosphorylation of c-Src on
Tyr418 (Chapter 2), which is located in its activation ioop. Interestingly, this effect of
H202 was completely attenuated by IGF-1R but flot by EGFR-PTK inhibitor, supporting
the idea that IGF-1R acts upstream of c-Src in inducing the effect of H202 in these cells.
c-Src lias been shown to be phosphorylated in 3T3-L1 preadipocytes in response to IGF-1
[229;230]. Thus, it appears that activation of the IGF-1R is followed by Src activation in
some ceil types.
PKB is implicated in many cellular functions, sucli as glucose transport, celI
growtli, gene expression, ceil survival and death as well as protein synthesis. PKB might
be recruited under physiological conditions at a certain basal level that contnbutes to the
normal function of the ceil in equilibnum with the other signaling pathways. The work
presented here has investigated PKB activation in response to severe oxidative stress. It
lias been shown previously that PKB phosphorylation under these conditions is transient
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(peaks at 10 minutes in AlO VSMC) and becomes rapidly inactivated within 60 minutes
of incubation with H202 [102]. Thus, it is possible that long time treatment with H202
might promote apoptotic pathways in the absence of an active PKB.
We have also demonstrated that, along with PKB phosphorylation, H202 induced
the phosphorylation of another non-receptor PTK, Pyk2, on Tyr402, which is the
autophosphorylation site and is critical for its activity. This response appears to be IGF
YR- but flot EGFR-dependent. Moreover, pharmacological inhibition of c-Src markedly
attenuated Pyk2 phosphorylation. Observations of Rocic et al. have suggested a role for
Pyk2 as an upstream regulator of P13-KIPKB pathway in VSMC in response to Angli
[204;205;209]. Thus, further investigation by using genetic approaches would be
necessary to prove the involvement of Pyk2 as a possible upstream molecule in ERK1/2
and PKB activation by H202 in AlO VSMC.
Taken together, we have demonstrated that IGF-IR serves as a mediator of H202-
induced activation of PKB, ERK1/2, Src and Pyk2 in AlO VSMC. Since ERK1/2, PKB
and Pyk2 are believed to play crucial roles in VSMC growth, hypertrophy, death and
survival, it may be suggested that targeting the IGF-1R could be a possible therapeutic
approach for vascular damage and remodeling caused by severe oxidative stress.
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figure 3.7: Effect of AG147$ and AG1024 on 11202-induced ERKT/2
phosphorylation in AlO VSMC. Confluent, serum-starved AlO ceils were pretreated
with (+) or without (-) 10 M AG1478 or 1 M AG1024 for 30 minutes, followed by
stimulation in the absence (C) or presence of 500 M H202 for 10 minutes. The celis
were lysed, and equal amounts of protein were separated on 7.5% SDS-PAGE. ERK1/2
phosphorylation was detected by immunoblotting with phospho-specific Thr202-
Tyr204/Thrl$5-Tyr187 ERK1/2 antibody (top panel). Blots were also analyzed for total
ERKI/2 (middle panel). The bottom panels represent average data quantified by
densitometric scanning of the immunoblots shown in the top panels. Values are the
means ± SE of at least 3 independent experiments and are expressed as percent
phosphorylation where phosphorylation observed with H202 alone is defined as 100%.
vs control (C), P<0.001 vs H202. (Unpublished data)
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Figure 3.8: Effect of AG1295 H202-induced PKB and ERK1/2 phosphorylation in
AlO VSMC. Confluent, serum-starved AlO ceils were pretreated with (+) or without t-)
10 M AG1295 for 30 minutes, followed by stimulation in the absence (C) or presence of
500 LM H202 for 10 minutes or lngImL PDGF for 5 minutes. The celis were lysed, and
equal amounts of protein were separated on 7.5% SDS-PAGE. PKB (A) and ERK1/2 (B)
phosphorylation were detected by immunoblotting with phospho-specific antibodies (top
panel of each section). Blots were also analyzed for total PKB and ERK1/2 (middle
panel). The bottom panels represent average data quantified by densitometnc scanning of
the immunoblots shown in the top panels. Values are the means ± SE of at least 3
independent experiments and are expressed as percent phosphorylation where
phosphorylation observed with either f1202 or PDGF alone is defined as 100%. (A)
vs control (C), #p<JJ vs control (C), tP<0.001 vs PDGF. (B) *P<0.001 vs
control (C), #p<J vs control (C), TP<0.001 vs PDGF. (Unpublished data)
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CHAPTER 4
CONCLUSION
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The resuits presented here demonstrate for the first time the involvement of the
IGF-IR in mediating H202-induced phosphorylation of PKB, Src and Pyk2 in VSMC.
These resuits were obtained by using AG1024, the specific pharmacological inhibitor of
IGF-1R-PTK. We provided further evidence for the implication of the IGF-1R in H202
signaling by showing that H202 enhanced the tyrosine phosphorylation of the f3—subunit
of this receptor, which was inhibited by AG1024. Moreover, we observed that AG1024
abrogated H202-induced ERK1/2 phosphorylation, which is in accord with recent studies
reporting a role for IGF-ÏR as an upstream modulator for ERK1/2 phosphorylation by
H202 in primary cultures of VSMC from SHR. On the other hand, H202-induced PKB
and ERK1/2 phosphorylation appeared to be EGFR- and PDGFR-independent in AlO
VSMC, since neither AG1478 nor AG1295 had any inhibitory effect on these F12O2-
induced responses. The precise mechanism by which H202 activates IGF-1R-PTK in AlO
celis remains unclear. However, considering the ability of H202 to inhibit protein tyrosÏne
phosphatases (PTPases), it may be suggested that H2O2 treatment can shift the
equilibrium of the phosphorylation-dephosphorylation cycle, resulting thereby in a net
increase of the tyrosine phosphorylation of IGF-1R andlor other proteins, which may
trigger the IGF-ÏR-PTK signaling pathway (Fig. 4.9).
Since ERKÏ/2 and PKB are critical mediators of celi growth, hypertrophy,
proliferation, protein synthesis and survival, it may be speculated that an aberrant
activation of these pathways by ROS could contribute to vascular remodeling (Fig. 4.9).
Moreover, targeting of IGf-1R could serve as a possible therapeutic approach in treating
cardiovascular diseases.
$1
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Figure 4.9: Schematic, hypothetica] model showing key steps in H202-evoked
responses in VSMC. IGF-YR activation appears to be necessary for H202-induced
phosphorylation of PKB, ERKÏ/2, c-Src and Pyk2 since ail of these events were blocked
by AG1024. Src appears to act upstream of Pyk2 and PKB, since its pharmacological
inhibition by PP2 decreased both Pyk2 and PKB phosphorylation. Whether Pyk2 is
acting upstream of PKB andlor ERKi/2 or not remains to be clarified. The mechanism by
which H202 stimulates IGF-iR3 phosphorylation is stiil unknown, but the ability of H202
to inhibit protein tyrosine phosphatases (PTPases) might contribute to this effect.
(Adapted from [231]).
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